Single Gut Procedure Helps Patients Keep Off Weight After Stopping GLP-1 Drugs
A one-time endoscopic procedure helped patients retain 78% of GLP-1-induced weight loss one year after stopping the medication.
Summary
A new endoscopic procedure called Revita, developed by Fractyl Health, may help people keep off weight after they stop taking GLP-1 drugs like Ozempic or Wegovy. In a small open-label study, participants who had lost at least 15% of their body weight on GLP-1 therapy retained about 78% of that weight loss one year after stopping the drug — following just one Revita procedure. Notably, one in three patients continued losing weight even after discontinuing GLP-1s. Blood sugar control also remained largely stable, which is significant since stopping GLP-1s often triggers metabolic backsliding. The procedure works by remodeling the lining of the duodenum and carries FDA Breakthrough Device designation. Larger randomized trial data are expected later in 2026.
Detailed Summary
For the millions of people taking GLP-1 medications like semaglutide or tirzepatide, one of the biggest concerns is what happens when they stop — rapid weight regain and metabolic deterioration are common. Fractyl Health's Revita procedure aims to solve this problem by addressing the underlying metabolic dysfunction in the gut, potentially making weight loss more durable without lifelong drug dependence.
The REVEAL-1 open-label cohort study followed 22 participants who had achieved at least 15% total body weight loss on GLP-1 therapy before receiving a single Revita procedure and then discontinuing their medication. At the one-year mark, participants had retained approximately 78% of their drug-induced weight loss — a striking result given that most patients regain the majority of lost weight within months of stopping GLP-1s. Mean total body weight change at one year was approximately 5.3–5.8%, depending on the analysis set used.
Perhaps equally important was metabolic stability. HbA1c — a key marker of blood sugar control — barely changed (0.08%), contrasting sharply with the significant glycemic worsening typically seen after GLP-1 withdrawal. Additionally, 33% of participants continued to lose weight even after stopping the drug, suggesting the procedure may reset metabolic set points rather than just temporarily suppressing appetite.
Safety data were reassuring: no procedure-related serious adverse events occurred, and only mild, transient side effects were reported in eight of 22 participants. Revita is a one-time endoscopic duodenal remodeling procedure, meaning it reshapes tissue in the small intestine without surgery.
However, critical caveats apply. The study is small (15 participants with complete efficacy data), open-label, and industry-sponsored. Randomized controlled trial data from REMAIN-1 are expected in late 2026 and will be essential for validating these early findings.
Key Findings
- Patients retained ~78% of GLP-1-induced weight loss one year after stopping medication following one Revita procedure.
- 33% of participants continued losing weight even after discontinuing GLP-1 therapy entirely.
- HbA1c remained nearly unchanged (0.08%), suggesting strong blood sugar stability post-GLP-1 withdrawal.
- No serious procedure-related adverse events were reported across 22 treated participants.
- Randomized REMAIN-1 trial midpoint data expected Q3 2026 will provide stronger evidence.
Methodology
This is a news report summarizing early-stage open-label clinical trial results (REVEAL-1 Cohort) from an industry press release by Fractyl Health. The evidence basis is preliminary: 22 participants for safety and only 15 with complete one-year efficacy data. Independent peer-reviewed publication and randomized controlled trial data are not yet available.
Study Limitations
The study is small, open-label, and industry-sponsored, all of which introduce significant risk of bias and limit generalizability. Only 15 of 22 participants had complete one-year efficacy data, further reducing statistical power. Peer-reviewed publication and independent replication are needed to confirm these results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.